FDA Issues Contingency Guidance for Trials Affected by COVID-19
March 19th 2020In guidance issued specifically in response to the COVID-19 pandemic, the FDA has advised that clinical trial protocol modifications may be made but must be documented and reported as promptly as possible. The FDA notes that trial participants may be sickened by COVID-19, supplies of investigational drugs may be interrupted, and quarantines and closings may make on-site patient visits impossible.
Amid COVID-19 Fears, Expert Panel Highlights Need for Biosimilars in the United States
March 19th 2020As the coronavirus (COVID-19) pandemic unfolded and disrupted pharmaceutical production, a panel of experts advocated for better education and legislation surrounding biosimilars in order to improve uptake in the United States and create affordable alternatives for patients.
FDA Overseas Inspection Policy Is Concerning, Says Biosimilars Patent Attorney
March 18th 2020Schiff Hardin patent attorney Imron T. Aly works with India-based manufacturers of biologics and says supply chain problems are anticipated shortly in the United States, based on FDA inspection policy and sourcing issues.
Nocebo Effect Is Difficult to Diagnose in Patients Switched to Biosimilars
March 17th 2020In inflammatory rheumatic diseases, the nocebo effect may account for a portion of treatment failures among patients who were placed on biosimilars; however, discontinuations due to the nocebo effect can be difficult to diagnose due to the absence of diagnostic criteria, differences in pathologic backgrounds for each disorder, and the absence of specific neurochemical and neuroimaging studies, investigators found.
US Drug Supply Could Be Affected by Insufficient Information on COVID-19
March 16th 2020Supplies of active pharmaceutical ingredients (API) are difficult to track and anticipate owing to limited information that manufacturers are required to provide, an issue that can make it difficult to respond to the COVID-19 pandemic, according to an interview with a Vizient executive.
Patent Thickets Are Not the Obstacle They Appear to Be, BIO Patent Counsel Claims
March 14th 2020Seen up close, many patents are not truly strong enough to block biosimilar commercialization, although patents filed after FDA approval of originator products can bar access to modern manufacturing methods, according to Hans Sauer, deputy general counsel and vice president for intellectual property at the Biotechnology Innovation Organization (BIO).
Amid COVID-19, FDA Switches to Remote Monitoring of Foreign Manufacturers
March 13th 2020In light of the COVID-19 outbreak, the FDA has suspended foreign inspections of FDA-regulated manufacturing plants and products. Meanwhile, escalating foreign travel restrictions put a damper on growth of the biosimilars industry.
Stakeholders Stress Need for Reliable Information, Streamlined Evidence Requirements
March 12th 2020Stakeholder comments at a biosimilars forum staged by the FDA and Federal Trade Commission focused on improving the quality of information being disseminated about biosimilars and the need to make the approval process less burdensome for manufacturers.
HHS Secretary Alex Azar Expresses Hope in Biosimilar Uptake, Notes Positive Momentum
March 11th 2020HHS Secretary Alex Azar discussed the future of biosimilars in the United States and the actions taken to ensure reductions in healthcare and prescription drug costs at the Biosimilars: Breaking Through the Barriers symposium in Washington, DC.
FDA/FTC Workshop Tackles Anticompetitive Practices That Hinder Biosimilar Uptake
March 9th 2020The conference was designed to further collaborative efforts between the FDA and the Federal Trade Commission (FTC) and generate public confidence in regulators’ commitment toward fostering a healthy biosimilars marketplace, but the goal is not to put manufacturers of innovator biologics on edge, said Stephen M. Hahn, commissioner of the FDA.
S&P Report Details Biosimilar Impact for Pharma Firms in Coming Years
March 6th 2020Growing awareness of biosimilars, patent expirations, and demands to lower healthcare costs are combining to increase uptake over the next 3 to 5 years, according to a recent S&P Global Ratings report. Some pharamceutical firms stand to gain, while others are more exposed.
FDA Releases Q&A for Industry With Details About Insulin Transition
March 5th 2020Looking to March 23, the FDA released a question-and-answer guidance document for industry about the upcoming transition for how certain products will now be approved under a biological pathway, including exceptions to the transition and how companies will receive notifications about their applications.
Supreme Court to Rule on ACA's Fate After 2020 Election
March 3rd 2020The Supreme Court will hear an appeal by a coalition of 20 mainly Democratic states, which are hoping for a reversal of a Fifth Circuit Court of Appeals ruling that held the Affordable Care Act’s (ACA) individual mandate is unconstitutional and called into question whether the remaining provisions of the law could still stand. However, a decision will not come until after the November 2020 presidential election.